Teacher Retirement System of Texas Grows Stake in Edwards Lifesciences Corporation $EW

Teacher Retirement System of Texas lifted its position in Edwards Lifesciences Corporation (NYSE:EW) by 88.1% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 377,974 shares of the medical research company’s stock after purchasing an additional 177,010 shares during the quarter. Teacher Retirement System of Texas owned about 0.06% of Edwards Lifesciences worth $29,395,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in EW. Brighton Jones LLC purchased a new stake in shares of Edwards Lifesciences in the 4th quarter valued at about $266,000. Farther Finance Advisors LLC grew its holdings in shares of Edwards Lifesciences by 24.4% during the second quarter. Farther Finance Advisors LLC now owns 10,954 shares of the medical research company’s stock worth $857,000 after purchasing an additional 2,146 shares in the last quarter. Park Avenue Securities LLC bought a new position in shares of Edwards Lifesciences in the second quarter worth approximately $315,000. Fifth Third Bancorp raised its stake in Edwards Lifesciences by 8.5% in the second quarter. Fifth Third Bancorp now owns 23,870 shares of the medical research company’s stock valued at $1,867,000 after purchasing an additional 1,865 shares in the last quarter. Finally, Ballentine Partners LLC raised its stake in Edwards Lifesciences by 18.8% in the second quarter. Ballentine Partners LLC now owns 6,072 shares of the medical research company’s stock valued at $475,000 after purchasing an additional 963 shares in the last quarter. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Stock Performance

NYSE EW opened at $83.70 on Friday. The company has a 50-day simple moving average of $84.99 and a two-hundred day simple moving average of $80.80. Edwards Lifesciences Corporation has a 12-month low of $65.94 and a 12-month high of $87.89. The firm has a market cap of $48.57 billion, a price-to-earnings ratio of 36.08, a PEG ratio of 3.22 and a beta of 0.95. The company has a quick ratio of 3.29, a current ratio of 4.00 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Thursday, October 30th. The medical research company reported $0.67 earnings per share for the quarter, beating analysts’ consensus estimates of $0.59 by $0.08. The company had revenue of $1.55 billion during the quarter, compared to analyst estimates of $1.49 billion. Edwards Lifesciences had a return on equity of 14.70% and a net margin of 23.25%.Edwards Lifesciences’s revenue for the quarter was up 14.7% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.67 EPS. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS and its Q4 2025 guidance at 0.580-0.640 EPS. On average, equities analysts forecast that Edwards Lifesciences Corporation will post 2.45 EPS for the current year.

Analysts Set New Price Targets

A number of research firms have commented on EW. Evercore ISI reissued an “outperform” rating and issued a $94.00 price target on shares of Edwards Lifesciences in a research note on Monday, January 5th. Citigroup reiterated a “buy” rating and issued a $101.00 target price (up from $96.00) on shares of Edwards Lifesciences in a research report on Thursday, December 11th. Mizuho increased their target price on Edwards Lifesciences from $90.00 to $100.00 and gave the company an “outperform” rating in a research note on Friday, October 31st. Raymond James Financial raised Edwards Lifesciences from a “market perform” rating to an “outperform” rating and set a $96.00 price target for the company in a research note on Monday, November 3rd. Finally, Stifel Nicolaus set a $110.00 price objective on Edwards Lifesciences and gave the stock a “buy” rating in a report on Tuesday. Three analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, nine have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $96.82.

Insider Buying and Selling at Edwards Lifesciences

In related news, VP Daniel J. Lippis sold 1,019 shares of the company’s stock in a transaction on Friday, January 9th. The shares were sold at an average price of $85.70, for a total transaction of $87,328.30. Following the completion of the sale, the vice president directly owned 22,002 shares in the company, valued at $1,885,571.40. This represents a 4.43% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, VP Donald E. Bobo, Jr. sold 11,340 shares of the stock in a transaction on Tuesday, January 6th. The shares were sold at an average price of $85.66, for a total transaction of $971,384.40. Following the sale, the vice president directly owned 31,870 shares of the company’s stock, valued at $2,729,984.20. The trade was a 26.24% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 57,824 shares of company stock worth $4,863,323. 1.29% of the stock is currently owned by insiders.

Edwards Lifesciences Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.